Shanghai United Imaging Healthcare Co., Ltd. (UIH, SSE: 688271) is a global leader in medical imaging, radiotherapy equipment, life science instruments, and digital healthcare solutions. With a market capitalization of approximately CNY 120 billion, UIH is listed on the Shanghai Stock Exchange’s STAR Market and is included in key indices such as the MSCI China All Shares Index, STAR 50, and CSI 300.

UIH employs over 8,500 professionals and serves more than 90 countries, with over 15,000 installations in medical and research institutions worldwide. The company is a pioneer in innovation, having launched over 140 cutting-edge products developed entirely in-house. Notable breakthroughs include the Total-Body PET/CT, HD TOF PET/MR, Whole-body UHF 5T MR, and the Fully Integrated CT-linac, all of which have earned global recognition for their industry-leading performance.

In 2024, UIH ranked first in China for new market share in comprehensive medical imaging products (excluding ultrasound and DSA), according to data from a reputable third-party commercial research firm. Internationally, the company has successfully expanded its high-end medical equipment footprint across over 90 countries and regions, including key markets such as the United States, Japan, France, Italy, and Germany, serving top clinical and research institutions. UIH’s global market share, customer satisfaction, and brand influence have grown rapidly.

Looking ahead, UIH will accelerate the registration and launch of next-generation products and innovative solutions. The company plans to deepen research collaborations, further strengthen its global marketing network, and enhance product capabilities to better meet evolving clinical demands. Through focused strategic development, robust execution, business growth, talent cultivation, and brand building, UIH is establishing a strong foundation for sustained global success.